Zelmac monotherapy shows promise in irritable bowel syndrome

Published: 2004-06-08 06:57:00

Updated: 2004-06-08 06:57:00

The single treatment of Zelmac (tegaserod), a drug for the treatment of abdominal pain or discomfort and constipation in women with irritable bowel syndrome (IBS) being developed by Switzerland-based Novartis, could be a significant advance in treating this disabling condition, according to a loc...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK